Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28588833 | 1.00 | F10 (0.43) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL28588834 | 1.00 | F10 (0.43) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL28582719 | 0.92 | F10 (0.45) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL28582722 | 0.92 | F10 (0.45) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL30180743 | 0.92 | F10 (0.45) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL25016738 | 0.88 | F10 (0.49) | F10MCHR1F2PRSS1 | |
| SCHEMBL28585736 | 0.88 | F10 (0.49) | F10MCHR1F2PRSS1 | |
| SCHEMBL25017552 | 0.85 | F10 (0.45) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL25015897 | 0.85 | F10 (0.45) | F10MCHR1F2PRSS1DRD4 | |
| SCHEMBL25017389 | 0.83 | F10 (0.46) | F10MCHR1F2PRSS1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | F10 1548/4885MCHR1 3680/4885F2 408/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | F10 1548/4885MCHR1 3680/4885F2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.